UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 46

Sortiert nach

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

Leukemia, 2010-04, Vol.24 (4), p.771-778

2010

Volltextzugriff (PDF)

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

Leukemia, 2010-03, Vol.24 (3), p.658-660

2010

Volltextzugriff (PDF)

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Leukemia, 2016-06, Vol.30 (6), p.1263-1272

2016

Volltextzugriff (PDF)

Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

Cytotherapy (Oxford, England), 2007, Vol.9 (6), p.539-547

2007

Volltextzugriff (PDF)

Relapsed multiple myeloma: who benefits from salvage autografts?

Internal medicine journal, 2013-02, Vol.43 (2), p.156-161

2013

Volltextzugriff (PDF)

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

Leukemia, 2015-01, Vol.29 (1), p.76-85

2015

Volltextzugriff (PDF)

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

Leukemia, 2013-05, Vol.27 (5), p.1201-1204

2013

Volltextzugriff (PDF)

The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma

Cytotherapy (Oxford, England), 2008, Vol.10 (5), p.507-517

2008

Volltextzugriff (PDF)

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL cells

Leukemia, 2009-06, Vol.23 (6), p.1205-1206

2009

Volltextzugriff (PDF)

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

Haematologica (Roma), 2013-06, Vol.98 (6), p.896-900

2013

Volltextzugriff (PDF)

TGF-[alpha] and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Leukemia, 2016-06, Vol.30 (6), p.1263

2016

Volltextzugriff (PDF)

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL super(+) cells

Leukemia, 2009-06, Vol.23 (6), p.1205-1206

2009

Volltextzugriff (PDF)

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone

Leukemia, 2015, Vol.29 (10), p.2101-2104

2015

Volltextzugriff (PDF)

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features

Blood cancer journal (New York), 2024-07, Vol.14 (1), p.116-5, Article 116

2024

Volltextzugriff (PDF)

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

The New England journal of medicine, 2020-12, Vol.383 (26), p.2526-2537

2020

Volltextzugriff (PDF)

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Blood advances, 2020-03, Vol.4 (6), p.1131-1144

2020

Volltextzugriff (PDF)

Study of chelating ion-exchange properties and electrical conductivity of terpolymer resins derived from p-Hydroxyacetophenone, Resorcinol and Glycerol

AIP Conference Proceedings, 2023, Vol.2839 (1)

2023

Volltextzugriff (PDF)

Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients

American journal of hematology, 2017-06, Vol.92 (6), p.508-514

2017

Volltextzugriff (PDF)

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Blood, 2019-11, Vol.134 (Supplement_1), p.1704-1704

2019

Volltextzugriff (PDF)

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

Blood, 2018-11, Vol.132 (Supplement 1), p.1802-1802

2018

Volltextzugriff (PDF)

The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders

Blood, 2018-11, Vol.132 (Supplement 1), p.3081-3081

2018

Volltextzugriff (PDF)

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

Blood, 2018-11, Vol.132 (Supplement 1), p.1826-1826

2018

Volltextzugriff (PDF)

A Geriatric Screening Tool (G8) Provides an Independent Prognostic Index for Azacitidine Treated Elderly MDS Patients

Blood, 2017-12, Vol.130, p.1692-1692

2017

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(41)

Publikationsform

Sprache

Englisch
(46)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(25)
Life Sciences & Biomedicine
(22)
Humans
(21)
Hematology
(19)
Female
(10)
Male
(9)
Oncology
(9)
Aged
(8)
Middle Aged
(8)
Adult
(6)
Kinases
(6)
Leukemia
(6)
Adolescent
(5)
Chronic Myeloid Leukemia
(5)
Health Aspects
(5)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(5)
Patients
(5)
Biological And Medical Sciences
(4)
Genetic Aspects
(4)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Pathology
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Blocking cytokine signaling along with intense Bcr-Abl kinase inhibition induces apoptosis in primary CML progenitors

Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy

TGF-α and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma

Relapsed multiple myeloma: who benefits from salvage autografts?

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

Proton pump inhibitors significantly increase the intracellular concentration of nilotinib, but not imatinib in target CML cells

The role of stem cell mobilization regimen on lymphocyte collection yield in patients with multiple myeloma

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL cells

Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells

TGF-[alpha] and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Short-term intense Bcr-Abl kinase inhibition with nilotinib is adequate to trigger cell death in BCR-ABL super(+) cells

A tale of two siblings: two cases of AML arising from a single pre-leukemic DNMT3A mutant clone

The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution

IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation

Myeloid neoplasms arising after methotrexate therapy for autoimmune rheumatological diseases do not exhibit poor-risk molecular features

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission

RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML

Study of chelating ion-exchange properties and electrical conductivity of terpolymer resins derived from p-Hydroxyacetophenone, Resorcinol and Glycerol

Dynamic assessment of RBC‐transfusion dependency improves the prognostic value of the revised‐IPSS in MDS patients

Deleterious Germline Variants, Especially in the DNA Repair Pathway, Are Common in Patients with Non-Related Multiple Cancers, One of Them Being Hematological Malignancy

Genetic Predisposition to Therapy-Related Myeloid Neoplasm By Rare, Deleterious Germline Variants in DNA Repair Pathway and Myeloid Driver Genes

The Mutation Profile of Myelodysplastic Syndrome Associated with Auto-Immune Rheumatological Disorders

Red Cell Alloimmunisation Is Associated with Increased Red Cell Transfusion Requirements in Myelodysplastic Syndrome

A Geriatric Screening Tool (G8) Provides an Independent Prognostic Index for Azacitidine Treated Elderly MDS Patients

Suchergebnisse filtern